A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Active, not recruiting · Phase 3 · NCT05070858
Conditions: Generalized Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $911,638
- U.S. investigators named
- 14
- Sites paid
- 17
- Planned or actual enrollment
- 288
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Pozelimab + Cemdisiran (drug), Cemdisiran (drug), Placebo (other), Pozelimab (drug)
- Dates
- Started 2021-12-14; completion 2028-11-11
- Results posted
- Not yet
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How the study drugs work inside the body * How much of the st…
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $911,638 in research payments for this study in 2025 (1,088 payments).
Products named: Veopoz
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Todd D. Levine, MD Neurology · Phoenix, AZ
- Said R. Beydoun, M.D. Neurology · Los Angeles, CA
- Ali A. Habib, MD Physical Medicine & Rehabilitation (PM&R) · Orange, CA
- Thomas D. Mcdonald, MD Neurology · Colorado Springs, CO
- William A. Justiz, MD Neurology · Naples, FL
- George G. Li, M.D. Specialist · Port Charlotte, FL
- Sashikumar Tharmarajah, MD Family Medicine · South Miami, FL
- Tuan H. Vu, MD Neurology · Tampa, FL
- Raghav Govindarajan, MD Physical Medicine & Rehabilitation (PM&R) · O Fallon, IL
- Jacob Rube, MD Neurology · Detroit, MI
- Timothy L. Schoonover, D.O. Neurology · Centerville, OH
- Sami L. Khella, MD Neurology · Philadelphia, PA
- Yessar M. Hussain, M.D. Physical Medicine & Rehabilitation (PM&R) · Austin, TX
- Aziz Shaibani, MD Neurology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Honorhealth Deer Valley Medical Center, AZ $202,639
- The University of South Florida Board of Trustees $197,736
- Houston Neurocare PA $175,557
- National Neuromuscular Research Institute PLLC $89,461
- Diverse Clinical Research LLC $83,673
- Hospital of Univ of Pennsylvania, PA $54,332
- Uci Health - Fountain Valley, CA $22,084
- Aqualane Clinical Research $20,786
- University of Southern California $15,556
- Medsol Clinical Research Center Inc $9,314
- $9,213
- Dayton Center for Neurological Disorders $8,899
- Clinical Biosafety Services LLC $7,250
- Wayne State University $6,240
- Prairieeducationresearchcooperativeperc $3,524
- Prairie Education Research Cooperative Perc $2,463
- Prairie Education & Research Cooperative Perc $1,911
- Colorado Springs Neurological Associates P C $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.